These include four kinases (Lyn, LCK, BTK and GSK3B) and one enzyme PLCG2 (phospholipase C family catalyzes the hydrolysis of phospholipids) that could be a therapeutic target for RTX-resistant and -sensitive BL. This evidence concerns the gene GSK3B and Burkitt lymphoma.